1. Home
  2. PERI vs CTNM Comparison

PERI vs CTNM Comparison

Compare PERI & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perion Network Ltd.

PERI

Perion Network Ltd.

HOLD

Current Price

$9.00

Market Cap

412.5M

Sector

Technology

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$12.08

Market Cap

507.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PERI
CTNM
Founded
1999
2009
Country
Israel
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
412.5M
507.0M
IPO Year
2005
2024

Fundamental Metrics

Financial Performance
Metric
PERI
CTNM
Price
$9.00
$12.08
Analyst Decision
Strong Buy
Buy
Analyst Count
3
5
Target Price
$14.75
$19.80
AVG Volume (30 Days)
412.6K
242.0K
Earning Date
02-18-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.46
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$9.95
N/A
Revenue Next Year
$1.07
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.00
$3.35
52 Week High
$11.44
$16.33

Technical Indicators

Market Signals
Indicator
PERI
CTNM
Relative Strength Index (RSI) 55.89 37.12
Support Level $8.82 $10.39
Resistance Level $9.15 $13.18
Average True Range (ATR) 0.26 1.19
MACD 0.04 -0.32
Stochastic Oscillator 75.74 7.64

Price Performance

Historical Comparison
PERI
CTNM

About PERI Perion Network Ltd.

Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: